{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:57:30Z","timestamp":1791205050664,"version":"4.1.0"},"reference-count":86,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) has overtaken viral hepatitis as the fastest-growing cause of hepatocellular carcinoma (HCC) in most high-income countries. What makes this epidemic clinically treacherous is a feature that distinguishes MASLD-related HCC from other aetiologies: roughly half of all cases arise in livers that have never progressed to cirrhosis, slipping through the net of conventional surveillance strategies. The molecular journey from fatty liver to malignancy unfolds through at least six interlocking programmes: lipotoxic rewiring of hepatocyte metabolism, including acquired lysosomal acid lipase (LAL) dysfunction, oncogenic glucose reprogramming through the p53-PUMA-mitochondrial pyruvate carrier (MPC) axis, and a preliminary MLKL\u2013Mfn2 axis linking metabolic stress to mitochondrial dysfunction; a chronic shift in the hepatic immune milieu toward tumour-permissive tolerance; gut microbiota dysbiosis flooding portal circulation with pro-inflammatory metabolites; progressive collapse of autophagic flux with p62\/SQSTM1 accumulation and lipolysosome formation; and pervasive epigenetic rewriting spanning DNA methylation, novel histone marks, and non-coding RNA networks. We also discuss emerging biomarkers and therapeutic strategies, closing with a brief note on Doublecortin-like kinase 1 (DCLK1) as a candidate marker at the intersection of cancer stem cell identity and immune microenvironment subversion.<\/jats:p>","DOI":"10.3389\/fonc.2026.1933386","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:50:02Z","timestamp":1791204602000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond fibrosis: the molecular roadmap from MASLD to hepatocellular carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Lorenzo","family":"Nevi","sequence":"first","affiliation":[{"name":"Microscopic and Ultrastructural Anatomy Research Unit, Departmental Faculty of Medicine, Surgery and Dentistry, Universit\u00e0 Campus Bio-Medico di Roma","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Altomare","sequence":"additional","affiliation":[{"name":"Gastroenterology and Endoscopy Unit, Departmental Faculty of Medicine, Surgery and Dentistry, Universit\u00e0 Campus Bio-Medico di Roma","place":["Rome, Italy"]},{"name":"Departmental Faculty of Science and Bio-Technology, Universit\u00e0 Campus Bio-Medico di Roma","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gallo","sequence":"additional","affiliation":[{"name":"Operative Research Unit of Clinical Medicine and Hepatology, Fondazione Policlinico Universitario Campus Bio-Medico","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Taffon","sequence":"additional","affiliation":[{"name":"Research Unit of Anatomical Pathology, Departmental Faculty of Medicine, Surgery and Dentistry, Universit\u00e0 Campus Bio-Medico di Roma","place":["Rome, Italy"]},{"name":"Anatomical Pathology Operative Research Unit, Fondazione Policlinico Universitario Campus Bio-Medico","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Musarra","sequence":"additional","affiliation":[{"name":"Department of Pathology, Ospedale San Camillo Forlanini","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Baiocchini","sequence":"additional","affiliation":[{"name":"Department of Pathology, Ospedale San Camillo Forlanini","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Carotti","sequence":"additional","affiliation":[{"name":"Microscopic and Ultrastructural Anatomy Research Unit, Departmental Faculty of Medicine, Surgery and Dentistry, Universit\u00e0 Campus Bio-Medico di Roma","place":["Rome, Italy"]},{"name":"Predictive Molecular Diagnostics, Fondazione Policlinico Universitario Campus Bio-Medico","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1159\/000550163","article-title":"The emerging challenge of non-cirrhotic MASLD-related hepatocellular carcinoma: etiology, immunopathology, and precision oncology","author":"Liu","year":"2025","journal-title":"Liver Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32758","article-title":"Global burden of liver cancer in males and females: changing etiological basis and the growing contribution of NASH","volume":"77","author":"Tan","year":"2023","journal-title":"Hepatology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL clinical practice guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2025.02.044","article-title":"Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis","volume":"169","author":"Younossi","year":"2025","journal-title":"Gastroenterology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101160","article-title":"MASLD-related HCC: multicenter study comparing patients with and without cirrhosis","volume":"6","author":"Vitellius","year":"2024","journal-title":"JHEP Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.02.030","article-title":"Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma","volume":"61","author":"Liu","year":"2014","journal-title":"J Hepatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29041","article-title":"The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells","volume":"65","author":"Bruschi","year":"2017","journal-title":"Hepatology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04991-0","article-title":"MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals","volume":"7","author":"Donati","year":"2017","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-320853","article-title":"Loss of hepatic Mboat7 leads to liver fibrosis","volume":"70","author":"Thangapandi","year":"2021","journal-title":"Gut"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-018-01533-x","article-title":"Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma","volume":"54","author":"Raksayot","year":"2019","journal-title":"J Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.003","article-title":"Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort","volume":"73","author":"Anstee","year":"2020","journal-title":"J Hepatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1247611","article-title":"Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.70047","article-title":"Rewriting the MASLD-associated hepatocellular carcinoma script: targeting epigenetics and metabolism","volume":"157","author":"Aiello","year":"2025","journal-title":"Int J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1705723","article-title":"Metabolic dysregulation in MASLD-associated HCC: diagnostic biomarkers and therapeutic opportunities","volume":"12","author":"Geng","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02357-x","article-title":"Lipid metabolism in homeostasis and disease","volume":"11","author":"Li","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03974-6","article-title":"Convergent somatic mutations in metabolism genes in chronic liver disease","volume":"598","author":"Ng","year":"2021","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.04.049","article-title":"Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis","volume":"75","author":"Pinyol","year":"2021","journal-title":"J Hepatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00049.2020","article-title":"An overview of deregulated lipid metabolism in nonalcoholic fatty liver disease with special focus on lysosomal acid lipase","volume":"319","author":"Carotti","year":"2020","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156113","article-title":"Lysosomal acid lipase activity is reduced both in cryptogenic cirrhosis and in cirrhosis of known etiology","volume":"11","author":"Vespasiani-Gentilucci","year":"2016","journal-title":"PLoS One"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04382-4","article-title":"Molecular and histological traits of reduced lysosomal acid lipase activity in the fatty liver","volume":"12","author":"Carotti","year":"2021","journal-title":"Cell Death Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-025-10939-8","article-title":"p53 regulates glucose metabolic reprogramming in MASLD-related hepatocellular carcinoma via modulating mitochondrial pyruvate carriers","volume":"20","author":"Wang","year":"2026","journal-title":"Hepatol Int"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1101\/2025.11.26.690789","article-title":"Hepatocyte MLKL drives obesity-driven hepatocellular carcinoma progression via mitochondrial dysfunction independent of necroptosis in MASLD","author":"Ohene-Marfo","year":"2025","journal-title":"bioRxiv"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01324-4","article-title":"Myeloid cells in chronic liver inflammation","volume":"22","author":"Patseas","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1569915","article-title":"The microenvironment in the development of MASLD-MASH-HCC and associated therapeutic in MASH-HCC","volume":"16","author":"Wu","year":"2025","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/biology15020148","article-title":"Immune determinants of MASLD progression: from immunometabolic reprogramming to fibrotic transformation","volume":"15","author":"Xu","year":"2026","journal-title":"Biology (Basel)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2026.1751290","article-title":"The macrophage opera: from metabolic prolog to oncogenic crescendo in metabolic dysfunction-associated steatotic liver disease","volume":"13","author":"Huang","year":"2026","journal-title":"Front Med (Lausanne)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0082-x","article-title":"The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"16","author":"Kazankov","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0044-z","article-title":"The immunology of hepatocellular carcinoma","volume":"19","author":"Ringelhan","year":"2018","journal-title":"Nat Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-326259","article-title":"CXCR2 inhibition enables NASH-HCC immunotherapy","volume":"71","author":"Leslie","year":"2022","journal-title":"Gut"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.09.003","article-title":"Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes","volume":"26","author":"Wolf","year":"2014","journal-title":"Cancer Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0379-5","article-title":"Platelet GPIbalpha is a mediator and potential interventional target for NASH and subsequent liver cancer","volume":"25","author":"Malehmir","year":"2019","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01344-3","article-title":"XCR1(+) type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis","volume":"27","author":"Deczkowska","year":"2021","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03233-8","article-title":"Auto-aggressive CXCR6(+) CD8 T cells cause liver immune pathology in NASH","volume":"592","author":"Dudek","year":"2021","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nature16969","article-title":"NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis","volume":"531","author":"Ma","year":"2016","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32336","article-title":"T cells: friends and foes in NASH pathogenesis and hepatocarcinogenesis","volume":"75","author":"Ramadori","year":"2022","journal-title":"Hepatology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-333154","article-title":"Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy","volume":"74","author":"Zhang","year":"2025","journal-title":"Gut"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nature24302","article-title":"Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity","volume":"551","author":"Shalapour","year":"2017","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000914","article-title":"Regulatory role and biomarker potential of gut microbiota metabolites in the progression of metabolic dysfunction-associated steatotic liver disease to hepatocellular carcinoma","volume":"16","author":"Che","year":"2025","journal-title":"Clin Transl Gastroenterol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.08.005","article-title":"Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development","volume":"71","author":"Mouries","year":"2019","journal-title":"J Hepatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH","volume":"57","author":"Zhu","year":"2013","journal-title":"Hepatology"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1186\/s13099-025-00782-5","article-title":"Gut microbiota and host transcriptome interactions reveal diagnostic biomarkers in MASLD-associated hepatocellular carcinoma","volume":"17","author":"Jinato","year":"2025","journal-title":"Gut Pathog"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.104996","article-title":"Cross talk between the liver microbiome and epigenome in patients with metabolic dysfunction-associated steatotic liver disease","volume":"101","author":"Pirola","year":"2024","journal-title":"EBioMedicine"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan5931","article-title":"Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells","volume":"360","author":"Ma","year":"2018","journal-title":"Science"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26146710","article-title":"Rifaximin attenuates liver fibrosis and hepatocarcinogenesis in a rat MASH model by suppressing the gut-liver axis and epiregulin-IL-8-associated angiogenesis","volume":"26","author":"Nishimura","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/140506","article-title":"A novel therapeutic approach to NASH: both polyethylene glycol 3350 and lactulose reduce hepatic inflammation in C57BL\/6J mice","volume":"30","author":"Gokcen","year":"2021","journal-title":"Adv Clin Exp Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000295","article-title":"Lactulose in cirrhosis: current understanding of efficacy, mechanism, and practical considerations","volume":"7","author":"Bloom","year":"2023","journal-title":"Hepatol Commun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1567849","article-title":"Lactitol may improve the prognosis of hepatocellular carcinoma through the proliferation of Megasphaera as well as Bifidobacterium","volume":"12","author":"Abiru","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.00850","article-title":"Lipophagy impairment is associated with disease progression in NAFLD","volume":"11","author":"Carotti","year":"2020","journal-title":"Front Physiol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1056","article-title":"Hepatic lipophagy: new insights into autophagic catabolism of lipid droplets in the liver","volume":"1","author":"Schulze","year":"2017","journal-title":"Hepatol Commun"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s44324-024-00022-5","article-title":"Autophagy and hepatic lipid metabolism: mechanistic insight and therapeutic potential for MASLD","volume":"2","author":"Raza","year":"2024","journal-title":"NPJ Metab Health Dis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164097","article-title":"ATP-citrate lyase links cellular metabolism to histone acetylation","volume":"324","author":"Wellen","year":"2009","journal-title":"Science"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27732","article-title":"DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma","volume":"61","author":"Villanueva","year":"2015","journal-title":"Hepatology"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-013-2692-z","article-title":"Increased alpha-tubulin1b expression indicates poor prognosis and resistance to chemotherapy in hepatocellular carcinoma","volume":"58","author":"Lu","year":"2013","journal-title":"Dig Dis Sci"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-12-0665","article-title":"RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma","volume":"11","author":"Ahn","year":"2013","journal-title":"Mol Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2025.1370","article-title":"FOXM1 influences DNA methylation to augment TACC3 alternative splicing directed by KAT2A in hepatocellular carcinoma","volume":"32","author":"Zhao","year":"2026","journal-title":"Clin Mol Hepatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21650","article-title":"Role of S-adenosyl-L-methionine in liver health and injury","volume":"45","author":"Mato","year":"2007","journal-title":"Hepatology"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-3342","article-title":"EZH2-mediated concordant repression of Wnt antagonists promotes beta-catenin-dependent hepatocarcinogenesis","volume":"71","author":"Cheng","year":"2011","journal-title":"Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3786","article-title":"Histone deacetylase HDAC8 promotes insulin resistance and beta-catenin activation in NAFLD-associated hepatocellular carcinoma","volume":"75","author":"Tian","year":"2015","journal-title":"Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217567","article-title":"Lactate drives senescence-resistant lineages in hepatocellular carcinoma via histone H2B lactylation of NDRG1","volume":"616","author":"Li","year":"2025","journal-title":"Cancer Lett"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.12.038","article-title":"TGM2-mediated histone serotonylation promotes HCC progression via MYC signalling pathway","volume":"83","author":"Dong","year":"2025","journal-title":"J Hepatol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2026.1805025","article-title":"Integrative transcriptomic analysis reveals miR-26a-5p downregulation and a potential predictive gene signature for the progression of metabolic liver disease","volume":"14","author":"Sorop","year":"2026","journal-title":"Front Cell Dev Biol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15682","article-title":"miR-21-5p promotes NASH-related hepatocarcinogenesis","volume":"43","author":"Rodrigues","year":"2023","journal-title":"Liver Int"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1172\/JCI63455","article-title":"MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis","volume":"122","author":"Tsai","year":"2012","journal-title":"J Clin Invest"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30671","article-title":"Circular RNA MAT2B promotes glycolysis and malignancy of hepatocellular carcinoma through the miR-338-3p\/PKM2 axis under hypoxic stress","volume":"70","author":"Li","year":"2019","journal-title":"Hepatology"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.02.021","article-title":"Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma","volume":"30","author":"Yang","year":"2022","journal-title":"Mol Ther"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.11.030","article-title":"Battle of the biopsies: role of tissue and liquid biopsy in hepatocellular carcinoma","volume":"80","author":"Lehrich","year":"2024","journal-title":"J Hepatol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s44355-025-00038-8","article-title":"Decoding the molecular and genomic landscape of hepatocellular carcinoma: biomarker discovery, classification frameworks, and therapeutic targeting","volume":"2","author":"Nevi","year":"2025","journal-title":"NPJ Gut Liver"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/apt.70428","article-title":"Research communication: changing aetiology of chronic liver diseases in East Asia Pacific and HCC surveillance in non-cirrhotic patients","volume":"63","author":"Liu","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2026.01.047","article-title":"Clinical care pathway for the risk stratification and management of patients with metabolic dysfunction-associated steatotic liver disease","volume":"171","author":"Kanwal","year":"2026","journal-title":"Gastroenterology"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.024","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","volume":"74","author":"Bianco","year":"2021","journal-title":"J Hepatol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.03.044","article-title":"Development and validation of a score for fibrotic nonalcoholic steatohepatitis","volume":"21","author":"Tavaglione","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000953","article-title":"HES V2.0 outperforms GALAD for detection of HCC: a phase 3 biomarker study in the United States","volume":"81","author":"El-Serag","year":"2025","journal-title":"Hepatology"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s10528-024-10667-y","article-title":"DCLK1 is overexpressed and associated with immune cell infiltration in hepatocellular carcinoma","volume":"62","author":"Velazquez-Enriquez","year":"2024","journal-title":"Biochem Genet"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31571","article-title":"DCLK1, a putative stem cell marker in human cholangiocarcinoma","volume":"73","author":"Nevi","year":"2021","journal-title":"Hepatology"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-025-01162-9","article-title":"Metabolic dysfunction-associated steatotic liver disease and steatohepatitis-associated hepatocarcinoma preclinical models","volume":"23","author":"Leslie","year":"2026","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1933386\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:50:04Z","timestamp":1791204604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1933386\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":86,"alternative-id":["10.3389\/fonc.2026.1933386"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1933386","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"1933386"}}